Literature DB >> 33169212

Characteristics associated with self-reported medication adherence in persons with psychosis referred to psychosocial rehabilitation centers.

Hélène Verdoux1,2,3, Clélia Quiles4, Laura Bon5, Isabelle Chéreau-Boudet6, Julien Dubreucq7,8, Emilie Legros-Lafarge9, Nathalie Guillard-Bouhet10, Catherine Massoubre11, Julien Plasse5, Nicolas Franck5,12.   

Abstract

The aim of the present study was to explore the characteristics of psychotropic treatment and of psychosocial functioning associated with self-reported medication adherence in persons with psychosis engaged in rehabilitation. The study was performed in the REHABase cohort including persons referred to a French network of psychosocial rehabilitation centers. Treatment adherence was assessed using the Medication Adherence Rating Scale (MARS). The associations between MARS score (categorized as "low" < 7 vs. "high" ≥ 7) and functioning or psychotropic treatment characteristics were explored using multivariate analyses in 326 participants with schizophrenia spectrum disorders. Regarding psychotropic treatment, high anticholinergic load was the only characteristic associated with poor medication adherence (adjusted OR, aOR 1.98, 95% CI 1.07-3.66). Regarding functioning measures, participants with poor medication adherence were more likely to present with lower stage of recovery (aOR 2.38, 95% CI 1.31-4.32), poor quality of life (aOR 2.17, 95% CI 1.27-3.71), mental well-being (aOR 1.68, 95% CI 1.03-2.72) and self-esteem (aOR 1.74, 95% CI 1.05-2.87), and higher internalized stigma (aOR 1.88, 95% CI 1.09-3.23). Self-reported poor medication adherence is a marker of poor functioning in persons with psychosis. The MARS is a quick and simple measure of adherence that may be helpful in clinical and rehabilitation settings to identify persons with specific rehabilitation needs.
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Functional outcome; Medication adherence; Psychosocial rehabilitation; Quality of life; Self-stigma

Mesh:

Year:  2020        PMID: 33169212     DOI: 10.1007/s00406-020-01207-x

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  49 in total

1.  Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects.

Authors:  H Verdoux; J Lengronne; F Liraud; B Gonzales; F Assens; F Abalan; J van Os
Journal:  Acta Psychiatr Scand       Date:  2000-09       Impact factor: 6.392

Review 2.  Compliance with medication regimens for mental and physical disorders.

Authors:  J A Cramer; R Rosenheck
Journal:  Psychiatr Serv       Date:  1998-02       Impact factor: 3.084

Review 3.  Assessment of adherence to oral antipsychotic medications: What has changed over the past decade?

Authors:  Dawn I Velligan; Natalie J Maples; Josie J Pokorny; Candace Wright
Journal:  Schizophr Res       Date:  2019-11-22       Impact factor: 4.939

Review 4.  Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.

Authors:  Stefan Leucht; Stephan Heres
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

Review 5.  Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder.

Authors:  Donald C Goff; Michele Hill; Oliver Freudenreich
Journal:  J Clin Psychiatry       Date:  2010       Impact factor: 4.384

Review 6.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

7.  Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.

Authors:  Somaia Mohamed; Robert Rosenheck; Joseph McEvoy; Marvin Swartz; Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2008-06-26       Impact factor: 9.306

8.  Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.

Authors:  Stefan Leucht; Magdolna Tardy; Katja Komossa; Stephan Heres; Werner Kissling; Georgia Salanti; John M Davis
Journal:  Lancet       Date:  2012-05-03       Impact factor: 79.321

9.  Recovery in psychosis: a Delphi study with experts by experience.

Authors:  Heather Law; Anthony P Morrison
Journal:  Schizophr Bull       Date:  2014-04-12       Impact factor: 9.306

Review 10.  Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review.

Authors:  Saínza García; Mónica Martínez-Cengotitabengoa; Saioa López-Zurbano; Iñaki Zorrilla; Purificación López; Eduard Vieta; Ana González-Pinto
Journal:  J Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.153

View more
  3 in total

1.  The central role of self-esteem in the quality of life of patients with mental disorders.

Authors:  Guillaume Barbalat; Julien Plasse; Emmanuel Gauthier; Hélène Verdoux; Clélia Quiles; Julien Dubreucq; Emilie Legros-Lafarge; Nematollah Jaafari; Catherine Massoubre; Nathalie Guillard-Bouhet; Frédéric Haesebaert; Nicolas Franck
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.996

2.  Dynamics between insight and medication adherence in first-episode psychosis: Study of 3-year trajectories.

Authors:  Julien Elowe; Julie Ramain; Alessandra Solida; Philippe Conus; Philippe Golay
Journal:  Eur Psychiatry       Date:  2022-08-15       Impact factor: 7.156

Review 3.  Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature.

Authors:  Giulia M Giordano; Francesco Brando; Pasquale Pezzella; Maria De Angelis; Armida Mucci; Silvana Galderisi
Journal:  Front Psychiatry       Date:  2022-08-30       Impact factor: 5.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.